The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
5 reports, 5 independent
Updated Fri 00:00
No new developments lately
Reached 3 outlets in its first 24 hours
- Reports
- 5
- Developments
- 4
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- A key meeting was held to review the Galleri blood test developed by GRAIL.Sub-event
- GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.Sub-event
Congress voted to allow Medicare reimbursement for Grail's Galleri test.1 source
FDA is evaluating GRAIL's Galleri multi-cancer early detection test for breakthrough status.1 source